{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:28:20Z","timestamp":1793968100147,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373721"],"award-info":[{"award-number":["82373721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159302"],"award-info":[{"award-number":["92159302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["RHM24202"],"award-info":[{"award-number":["RHM24202"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0506100"],"award-info":[{"award-number":["2023ZD0506100"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0506106"],"award-info":[{"award-number":["2023ZD0506106"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119404","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:49:30Z","timestamp":1791672570000},"page":"119404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Design, synthesis and biological evaluation of novel aminopyrimidine derivatives as potent EGFRC797S inhibitors for overcoming osimertinib resistance"],"prefix":"10.1016","volume":"321","author":[{"given":"Yuying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-5101","authenticated-orcid":false,"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119404_bib1","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119404_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119404_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1590\/1414-431X20144099","article-title":"Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data","volume":"47","author":"Jorge","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.119404_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.001","article-title":"Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures","volume":"174","author":"Lee","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119404_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2174\/187152061405140501101624","article-title":"Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer","volume":"14","author":"Passaro","year":"2014","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119404_bib10","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100624","article-title":"EGFR-T790M mutation-derived interactome rerouted EGFR translocation contributing to gefitinib resistance in non-small cell lung cancer","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ejmech.2026.119404_bib12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119404_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, A randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejmech.2026.119404_bib14","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119404_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119404_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib18","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2026.119404_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116106","article-title":"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation","volume":"265","author":"Zuo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib21","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119404_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-0699","article-title":"Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation","volume":"20","author":"Yang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib25","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2014.58.8293","article-title":"Intratumoral heterogeneity of ALK-rearranged and ALK\/EGFR coaltered lung adenocarcinoma","volume":"33","author":"Cai","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119404_bib26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.lungcan.2012.04.012","article-title":"Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation","volume":"77","author":"Lee","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117323","article-title":"Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR\/ALK co-mutations","volume":"287","author":"He","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib28","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/cncr.34757","article-title":"Targeted therapy for lung cancer: beyond EGFR and ALK","volume":"129","author":"Herrera-Ju\u00e1rez","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1541-7786.MCR-16-0211","article-title":"Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer","volume":"15","author":"Miyawaki","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119404_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-15-0084","article-title":"Activation of EGFR bypass signaling by TGF\u03b1 overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells","volume":"15","author":"Tani","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2026.119404_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117722","article-title":"Progression and expansion of ALK inhibitors against NSCLC: a dual target approach","volume":"293","author":"Kumari","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.33385","article-title":"Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a global, phase 2 study","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib37","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119404_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.05.010","article-title":"Penetration of the blood-brain barrier by avitinib and its control of intra\/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation","volume":"122","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119404_bib40","first-page":"625","article-title":"A Dichloropropionamide-Substituted diaminopyrimidine EGFR-TKI overcomes osimertinib resistance in NSCLC via dual anchoring at Ser797 and Met793","volume":"69","author":"Wang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib41","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejmech.2026.119404_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00006676-200110000-00009","article-title":"Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression","volume":"23","author":"Poch","year":"2001","journal-title":"Pancreas"},{"key":"10.1016\/j.ejmech.2026.119404_bib43","first-page":"155","article-title":"[Epithelial-mesenchymal Transition: Biological Basis and Clinical Prospects of Lung Cancer Invasion, Metastasis, and Drug Resistance]","volume":"28","author":"Sun","year":"2025","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.ejmech.2026.119404_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cpt.2024.07.001","article-title":"Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)","volume":"3","author":"Dela Cruz","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.ejmech.2026.119404_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114889","article-title":"Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: in vitro screening and ADME predictions","volume":"245","author":"Kardile","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119404_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119404_bib48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.32604\/or.2025.059311","article-title":"Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies","volume":"33","author":"Li","year":"2025","journal-title":"Oncol. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:57:45Z","timestamp":1793966265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":43,"alternative-id":["S0223523426008494"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119404","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel aminopyrimidine derivatives as potent EGFRC797S inhibitors for overcoming osimertinib resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119404"}}